WHO ICTRP trial
Early-life stress, the endocannabinoid system, and fear memory extinction
EUCTR2017-004823-66-NL · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2017-004823-66-NL |
|---|---|
| Public title | Early-life stress, the endocannabinoid system, and fear memory extinction |
| Scientific title | Early-life stress, the endocannabinoid system, and fear memory extinction |
| Primary sponsor | Radboudumc |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Netherlands |
| Conditions | healthy volunteers MedDRA version: 20.0 Level: LLT Classification code 10036876 Term: Prolonged posttraumatic stress disorder System Organ Class: 100000004873 ;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03] |
| Interventions | Product Name: Namisol Product Code: ECP002A Pharmaceutical Form: Tablet INN or Proposed INN: Namisol CAS Number: 1972-08-03 Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL Concentration unit: mg milligram(s) Concentration type: equal… |
| Registration date | Mar 19, 2019 |
| Target size | 96 |
| Secondary IDs | ELTCAN1 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: